We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amedisys Ties Up With Medalogix to Boost Home Health Unit
Read MoreHide Full Article
Amedisys, Inc. (AMED - Free Report) recently announced a minority equity investment in Medalogix — a Home Health and Hospice predictive modeling and analytics company in Nashville.
Per Amedisys, this partnership will help it to progress with respect to the latest and differentiated payment models. Further, Amedisys expects to strengthen partnerships with Managed Care Organizations and drive patient insights required for risk arrangements using the Medalogix platform.
Home Health and Hospice Opportunities Galore
In November 2017, Centers for Medicare and Medicaid Services (CMS) issued a final rule to update and revise the 2018 Medicare home health reimbursement rates without finalizing the Home Health Groupings Model (HHGM), which was proposed to be implemented in 2019. With this, CMS projects a decline of 0.4% in reimbursement to home health providers resulting from the payment provisions of the final rule.
According to home health players like Amedisys, HHGM is one of the most significant regulatory proposals and has the potential to hurt the industry. Amedisys is currently leaving no stone unturned to benefit from this situation. It is striving to improve the quality of care as well as implement disease management programs at hospitals. The company is also working on expanding its business by garnering more referrals from hospitals.
Amedisys also expects to be able to cope up with the ongoing “shift to value” in the healthcare industry by taking the necessary steps. Per management, CMS’ three-pronged strategy aims at enhanced individual patient care, improved health outcomes and cost reduction.
Furthermore, there has been a surge in Medicare Advantage enrollment. Moreover, payors are forming new partnerships that allow patients to receive care in the home. Thus, management believes by combining new technology with home health services, Amedisys might be able to gain an edge over competitors and exploit the increasing opportunities in the niche market.
Market Potential
The home health industry is poised for tremendous growth, courtesy of an aging U.S. population, patients’ desire for independence and home health as a cheaper care modality. The company should continue to benefit from the aging demographics of the U.S. population and the need for higher acuity patients to be taken care of in a home nursing environment.
Going by a report by Grand View Research, the global home healthcare market is expected to see a CAGR of 7.8% between 2014 and 2025.
Share Price Movement
Amedisys has been gaining investor confidence on consistently positive results. Over the past year, the company’s share price has outperformed its industry. The stock has gained 134.5% in comparison with the industry’s 22.8% rise.
Zacks Rank & Other Key Picks
Amedisys currently carries a Zacks Rank #1 (Strong Buy).
A few other top-ranked stocks in the broader medical space are Integer Holdings Corporation (ITGR - Free Report) , Intuitive Surgical (ISRG - Free Report) and Masimo Corporation (MASI - Free Report) .
Intuitive Surgical’s long-term expected earnings growth rate is 14.7%. The stock carries a Zacks Rank #1.
Masimo’s long-term expected earnings growth rate is 14.8%. The stock has a Zacks Rank #2.
5 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Image: Bigstock
Amedisys Ties Up With Medalogix to Boost Home Health Unit
Amedisys, Inc. (AMED - Free Report) recently announced a minority equity investment in Medalogix — a Home Health and Hospice predictive modeling and analytics company in Nashville.
Per Amedisys, this partnership will help it to progress with respect to the latest and differentiated payment models. Further, Amedisys expects to strengthen partnerships with Managed Care Organizations and drive patient insights required for risk arrangements using the Medalogix platform.
Home Health and Hospice Opportunities Galore
In November 2017, Centers for Medicare and Medicaid Services (CMS) issued a final rule to update and revise the 2018 Medicare home health reimbursement rates without finalizing the Home Health Groupings Model (HHGM), which was proposed to be implemented in 2019. With this, CMS projects a decline of 0.4% in reimbursement to home health providers resulting from the payment provisions of the final rule.
According to home health players like Amedisys, HHGM is one of the most significant regulatory proposals and has the potential to hurt the industry. Amedisys is currently leaving no stone unturned to benefit from this situation. It is striving to improve the quality of care as well as implement disease management programs at hospitals. The company is also working on expanding its business by garnering more referrals from hospitals.
Amedisys also expects to be able to cope up with the ongoing “shift to value” in the healthcare industry by taking the necessary steps. Per management, CMS’ three-pronged strategy aims at enhanced individual patient care, improved health outcomes and cost reduction.
Furthermore, there has been a surge in Medicare Advantage enrollment. Moreover, payors are forming new partnerships that allow patients to receive care in the home. Thus, management believes by combining new technology with home health services, Amedisys might be able to gain an edge over competitors and exploit the increasing opportunities in the niche market.
Market Potential
The home health industry is poised for tremendous growth, courtesy of an aging U.S. population, patients’ desire for independence and home health as a cheaper care modality. The company should continue to benefit from the aging demographics of the U.S. population and the need for higher acuity patients to be taken care of in a home nursing environment.
Going by a report by Grand View Research, the global home healthcare market is expected to see a CAGR of 7.8% between 2014 and 2025.
Share Price Movement
Amedisys has been gaining investor confidence on consistently positive results. Over the past year, the company’s share price has outperformed its industry. The stock has gained 134.5% in comparison with the industry’s 22.8% rise.
Zacks Rank & Other Key Picks
Amedisys currently carries a Zacks Rank #1 (Strong Buy).
A few other top-ranked stocks in the broader medical space are Integer Holdings Corporation (ITGR - Free Report) , Intuitive Surgical (ISRG - Free Report) and Masimo Corporation (MASI - Free Report) .
Integer Holdings’ expected long-term earnings growth rate is 15%. The stock sports a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Intuitive Surgical’s long-term expected earnings growth rate is 14.7%. The stock carries a Zacks Rank #1.
Masimo’s long-term expected earnings growth rate is 14.8%. The stock has a Zacks Rank #2.
5 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Click to see them right now >>